The US FDA has approved a new drug-releasing stent for percutaneous transluminal coronary angioplasty in the treatment of femoropopliteal occlusive disease. The stent is coated with a therapeutic dose of the chemotherapy agent paclitaxel. The authorization application was supported by a prospective study carried out in 54 sites all over the world on more than 1000 patients. The results of a study on another stent were also published. This is intended for the treatment of stenosis and restenosis lesions and combines two new coating technologies. One is for the minimization of metal/tissue interactions, while the other is drug-releasing. Results are supported by two studies on
efficacy.
FDA approves new stent
